Government caps trade margins on 137 anti-cancer drugs at 30%

Governance & Public Health Policy · 18 October 2026 · Based on Indian Express (original report)

Worth reading — New development — both a Prelims fact and a Mains debate, no past question yet.

2-minute summary

The Central Government has capped trade margins on 137 non-scheduled anti-cancer medicines at 30% over the cost at the first point of sale (stockist or hospital). Issued via a gazette notification taking effect on November 9, 2026, the directive applies to critical cancer therapies, including patented drugs such as pembrolizumab, ribociclib, and abemaciclib. Manufacturers must submit revised MRPs to the National Pharmaceutical Pricing Authority (NPPA) within seven days. Market analysis revealed that non-scheduled cancer drugs carried exorbitant average trade mark-ups of 170%, reaching up to 700% in extreme cases. The 30% margin cap (equivalent to a 42.86% mark-up on Price to Stockist) is projected to reduce retail prices by 20% to 70%, generating annual patient savings of approximately ₹2,500 crore. To prevent artificial supply shortages, manufacturers are legally barred from reducing monthly production levels or discontinuing these formulations without prior NPPA approval.

Why it's in the news

The Ministry of Chemicals and Fertilizers notified a 30% trade margin cap on 137 anti-cancer drugs in October 2026. This regulatory intervention targets inflated mark-ups on non-scheduled life-saving medicines to drastically lower out-of-pocket healthcare expenses for cancer patients.

Facts to remember

• In October 2026, the Central government capped trade margins on 137 non-scheduled anti-cancer drugs at 30% of Maximum Retail Price (excluding GST).
• The National Pharmaceutical Pricing Authority (NPPA) functions as an attached office under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
• Out of India's ₹12,500 crore annual cancer drug market, regulated scheduled drugs account for only about ₹2,250 crore.
• The trade margin cap allows a maximum mark-up of 42.86% over the Price to Stockist (PTS) or Price to Distributor (PTD).
• Under NPPA notification rules, drug manufacturers must seek prior permission before reducing monthly production levels or discontinuing capped formulations.

Background and context

Drug pricing in India is governed by the Drug Prices Control Order (DPCO), 2013, promulgated under Section 3 of the Essential Commodities Act, 1955. NPPA regulates prices through two primary mechanisms: direct ceiling price fixation for scheduled formulations listed in the National List of Essential Medicines (NLEM), and trade margin rationalisation (TMR) for non-scheduled drugs. Non-scheduled drugs are generally subject to a self-regulatory cap permitting maximum annual MRP increases of up to 10%. However, excessive trade margins charged by intermediaries led to distorted retail prices, especially in high-value therapeutic segments like oncology. In 2019, NPPA successfully piloted TMR on 42 anti-cancer medicines, reducing MRPs by up to 91% and saving patients ₹984 crore annually. The October 2026 intervention expands this approach to 137 formulations based on recommendations by an expert committee under the Director General of Health Services (DGHS).

Constitutional provisions

• Article 21 — Interpreted by the Supreme Court as guaranteeing the Right to Health and affordable medical care as integral components of the Right to Life.
• Article 47 — Directive Principle mandating the State to raise the level of nutrition and standard of living and to improve public health as among its primary duties.

Committees and reports

• DGHS Expert Committee on Essentiality of Cancer Drugs — Identified and recommended 137 critical non-scheduled anti-cancer drugs for trade margin rationalisation to enhance affordability.
• Tata Memorial Hospital Real-World Cancer Care Study — Highlighted that high drug costs prevent 98.4% of eligible Indian patients from accessing advanced patented targeted cancer therapies.

Government schemes

• National Pharmaceutical Pricing Authority (NPPA) Framework — Enforces DPCO provisions, fixes ceiling prices, monitors drug availability, and prevents overcharging by pharmaceutical companies.
• Ayushman Bharat - Pradhan Mantri Jan Arogya Yojana (PM-JAY) — Provides secondary and tertiary health insurance coverage up to ₹5 lakh per family per year, benefiting from lowered oncology drug prices.

Mains practice: High out-of-pocket expenditure on critical care drugs remains a major bottleneck in achieving Universal Health Coverage in India. Examine how trade margin rationalisation on non-scheduled medicines addresses this structural challenge.

Out-of-pocket expenditure (OOPE) accounts for nearly 47% of total health expenditure in India, with medicine costs contributing over two-thirds of this burden. The October 2026 directive by the National Pharmaceutical Pricing Authority (NPPA) capping trade margins on 137 anti-cancer drugs at 30% marks a key intervention to curb catastrophic healthcare spending.

• Legal and Regulatory Anchor: The measure derives power from the Drug Prices Control Order (DPCO), 2013, issued under Section 3 of the Essential Commodities Act, 1955. By moving beyond scheduled drugs under the National List of Essential Medicines (NLEM), NPPA addresses market failures in non-scheduled segments.

• Curbing Market Distortions: Prior to this order, non-scheduled oncology drugs carried average trade mark-ups of 170%, reaching up to 700%. Capping margins at 30% of MRP (a 42.86% mark-up on Price to Stockist) directly curbs profiteering by supply-chain intermediaries without forcing manufacturers to sell below production cost.

• Socio-Economic Impact: Out of India's ₹12,500 crore cancer drug market, scheduled drugs constitute only ₹2,250 crore. A Tata Memorial Hospital study revealed that high costs prevent 98.4% of patients from accessing required targeted therapies. The expected 20–70% price drop will generate ₹2,500 crore in annual patient savings, upholding the mandate under Article 47.

• Supply Security Safeguards: To avert artificial market scarcity, the notification legally obliges manufacturers to maintain existing production levels and seek mandatory NPPA permission before reducing output or discontinuing formulations.

Way Forward:

• Expanding NLEM Framework: Periodically update NLEM to include advanced targeted biologicals and immunotherapies.

• Strengthening Generic Competition: Promote Jan Aushadhi Kendras and enforce prescription of generic names under National Medical Commission guidelines.

• Leveraging TRIPS Flexibilities: Utilize compulsory licensing under Section 84 of the Patents Act, 1970, when patented drug prices remain prohibitive.

Regulating exorbitant trade margins aligns public health governance with Article 21, advancing Sustainable Development Goal 3 (Good Health and Well-being) while preserving commercial sustainability for pharmaceutical firms.

Prelims practice questions

Q1. With reference to drug price regulation in India, consider the following statements: 1. The National Pharmaceutical Pricing Authority (NPPA) operates as an attached office under the Ministry of Health and Family Welfare. 2. Trade margin capping on non-scheduled anti-cancer formulations applies at the point of sale to stockists or direct hospital buyers. 3. Pharmaceutical manufacturers intending to discontinue capped formulations must obtain prior permission from the NPPA. How many of the above statements are correct?

1. Only one
2. Only two
3. All three
4. None

Answer: B. Statement 1 is incorrect because NPPA functions under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, not the Ministry of Health and Family Welfare. Statement 2 is correct because trade margin caps apply at the first point of sale (stockist or direct hospital purchaser). Statement 3 is correct because the NPPA order explicitly mandates prior permission before reducing monthly production levels or discontinuing supply.

Q2. Consider the following statements regarding the Drug Prices Control Order (DPCO) framework in India: 1. Scheduled formulations listed under the National List of Essential Medicines (NLEM) are subject to direct ceiling price fixation by the NPPA. 2. Non-scheduled drugs are generally allowed a maximum automatic retail price escalation of up to 10% over a 12-month period. 3. Quantities of medicines provided free under Patient Assistance Programmes are strictly included in calculating the baseline Price to Stockist for trade margin caps. Which of the statements given above are correct?

1. 1 and 2 only
2. 2 and 3 only
3. 1 and 3 only
4. 1, 2 and 3

Answer: A. Statements 1 and 2 are correct: NLEM formulations have prices capped directly by NPPA, while non-scheduled formulations are monitored to ensure annual MRP increases do not exceed 10%. Statement 3 is incorrect because free medicines provided to patients under documented Patient Assistance Programmes are excluded from the baseline Price to Stockist calculation, provided patient details are furnished to NPPA.

Q3. With reference to pharmaceutical market regulation, which of the following best describes the mechanism of 'Trade Margin Rationalisation' (TMR)?

1. Fixing a uniform baseline manufacturing cost for all patented and generic formulations across India.
2. Capping the percentage mark-up between the price to distributor and the maximum price paid by consumers.
3. Mandating foreign drug firms to transfer production technologies to domestic firms prior to market launch.
4. Waiving all statutory central goods and services taxes on essential biological therapies and vaccines.

Answer: B. Option B is correct. Trade Margin Rationalisation (TMR) is a regulatory tool where the government caps the margin (mark-up) that trade channels (wholesalers, stockists, retailers, hospitals) can add over the price at which the manufacturer sells to the distributor (PTS/PTD), thereby directly lowering the final MRP without directly fixing manufacturing costs. Options A, C, and D describe unrelated policy mechanisms.

Revision flashcards

• Which ministry and department govern the National Pharmaceutical Pricing Authority (NPPA)? NPPA is an attached office under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
• What is the structural difference between Scheduled and Non-Scheduled drugs under DPCO 2013? Scheduled drugs (listed in NLEM) have capped ceiling prices. Non-scheduled drugs have price increases monitored and capped at 10% annually.
• In October 2026, what specific trade margin ceiling was imposed on 137 anti-cancer drugs? A 30% cap on trade margins over the Price to Stockist/Distributor (excluding GST), corresponding to a 42.86% mark-up.
• In October 2026, what condition was mandated for drugmakers regarding production levels of capped oncology drugs? Manufacturers must maintain production levels and cannot reduce output or discontinue formulations without prior NPPA approval.
• Why is Trade Margin Rationalisation preferred over direct ceiling pricing for non-scheduled drugs? It curbs excessive intermediary mark-ups while allowing market-driven baseline prices, maintaining drug availability without disincentivising manufacturing.